Drugs for the gynecologist to prescribe in the prevention of breast cancer: Current status and future trends

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 5, 2000, Pages 1121-1126

  Goldstein, Steven R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Raloxifene; Selective estrogen receptor modulators; SERMs; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFECT; ENDOMETRIUM HYPERPLASIA; ESTROGEN ACTIVITY; FEMALE; GYNECOLOGY; HUMAN; LUNG EMBOLISM; POLYP; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; UTERUS CARCINOMA;

EID: 0034079924     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.105941     Document Type: Article

References (25)

1. 1. American Cancer Society. Cancer facts and figures - 1998. Atlanta (GA): The Society; 1998.
2. 2. Hammond CB. Women's concerns with hormone replacement therapy - compliance issues. Fertil Steril 1994;625:157-60.
3. 3. Morrow M. Breast cancer: Who and why? In: Jordan VC, editor. Tamoxifen. A guide for clinicians and patients. Huntington (NY): PRR,; 1996. p. 1-14.
4. 4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
5. 5. Jordan VC. Designer estrogens. Sci Am 1998;279:60-7.
6. 6. Colditz GA, Hankinson SE, Hunter DJ, Willett SC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
7. 7. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
8. 8. Early Breast Cancer Trialists' Collaborative Group. Effects of tamoxifen and of cytoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92.
9. 9. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1415-67.
10. 10. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
11. 11. Lippman ME, Osborne CK, Knazek R, Young N. In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med 1977;296:154-9.
12. 12. Osborne CK, Hobbs K, Clark G. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985;45:584-90.
13. 13. Jordan VC, Allen KE. Evaluation of the antitumor activity of the nonsteroidal antiestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma mode. Eur J Cancer 1980;16:239-51.
14. 14. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
15. 15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
16. 16. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
17. 17. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Prevention Study. Lancet 1998;352:93-7.
18. 18. Giri DD, Dundas SA, Nottingham JF, Underwood JC. Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: an immunohistological study. Histopathology 1989;15:575-84.
19. 19. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992;69:1174-81.
20. 20. Hol T, Cox MB, Bryant HU, Draper MW. Selective estrogen receptor modulators and postmenopausal women's health. J Womens Health 1997;6:523-31.
21. 21. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988;45:344-5.
22. 22. Neven P, Muylder X, Van Belle Y, Vanderick G, De Mylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990;35:235-8.
23. 23. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. Effect of raloxifene, estrogen, and placebo on the postmenopausal endometrium: a 12 month comparative study. Obstet Gynecol 2000;95:95-103.
24. 24. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cattley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
25. 25. Schwartz LB, Snyder J, Horan C, Porgess RF, Nachtigall LE, Goldstein SR. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. Ultrasound Obstet Gynecol 1997;10:1-6.